Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766578 | 0.83 | MEN1 (0.40) | KMT2ANR1H2NR1H3ALDH1A1POLB | |
| SCHEMBL6004982 | 0.80 | AXL (0.40) | KMT2AALOX15KDM4EALDH1A1RAB9A | |
| SCHEMBL455865 | 0.80 | SMN1; SMN2 (0.46) | AKT2L3MBTL1KMT2AAKT1NR1H2 | |
| SCHEMBL456840 | 0.80 | IKBKB (0.43) | NR1H2NR1H3KDM4EPOLBALPL | |
| SCHEMBL2766385 | 0.77 | BTK (0.41) | AKT2CHEK1L3MBTL1KMT2ABTK | |
| SCHEMBL458788 | 0.75 | BTK (0.36) | AKT2CHEK1L3MBTL1KMT2ABTK | |
| SCHEMBL3632831 | 0.73 | BTK (0.46) | L3MBTL1BTKALOX15KDM4EALDH1A1 | |
| SCHEMBL4637112 | 0.73 | KMT2A (0.46) | KMT2ANR1H2NR1H3ALOX15KDM4E | |
| SCHEMBL577704 | 0.71 | L3MBTL1 (0.45) | AKT2L3MBTL1KMT2ABTKALOX15 | |
| SCHEMBL1821061 | 0.71 | NR1H2 (0.42) | NR1H2NR1H3KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | claimed |
| EP-2001848-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF DEMENTIA | MERCK SHARP & DOHME LTD. (GB) | 2008-12-17 | — | — | EP | claimed |
| WO-2007110667-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF DEMENTIA | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-04 | — | — | WO | claimed |
| EP-2614053-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012033225-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-15 | — | — | WO | disclosed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1266911-B1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| EP-2120584-A1 | SILYLATED PIPERIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| EP-2001848-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF DEMENTIA | MERCK SHARP & DOHME LTD. (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| EP-1414825-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1412362-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011868-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-02-13 | — | — | US | disclosed |
| WO-2003008422-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
| EP-1266911-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | BRAP, MCM4, BOLA2; BOLA2B | AKT2 3109/4885CHEK1 1098/4885L3MBTL1 3636/4885 |
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | AKT2 3588/4885CHEK1 4323/4885L3MBTL1 3281/4885 |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | AKT2 3371/4885CHEK1 2073/4885L3MBTL1 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.